Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin
- PMID: 24561246
- DOI: 10.1016/j.ygyno.2014.02.020
Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin
Abstract
Objective: Oral progestin is an alternative to hysterectomy for women with complex atypical hyperplasia (CAH) or grade one endometrial cancer (G1EC) who wish fertility preservation. We evaluated treatment efficacy and fertility outcomes in this population.
Methods: Women <45 y treated with oral progestin for CAH or G1EC were identified from two cancer centers. Data were obtained from medical records and telephone questionnaires. Time until complete response (CR), and from CR until recurrence was censored for patients without events and analyzed for associations with patient and treatment characteristics; cumulative incidence functions were used to estimate event probability over time.
Results: 44 patients were identified, 19 (43%) with CAH and 25 (57%) with G1EC. Median age was 36.5 y (26-44). 24 (55%) achieved CR (median time: 5.7 months). Older age was associated with a lower likelihood of CR (HR 0.84, p=0.0003, 95% CI, 0.8-0.9). CR probability appeared to plateau after 12 months of therapy. Among those with CR, 13 (54%) recurred (median time 3.5 y). 24 patients (55%) underwent hysterectomy; 3 (13%) were upstaged. 11 (25%) underwent fertility treatment with the following outcomes: 6 (55%) no pregnancy, 2 (18%) at least one live infant, and 3 (27%) spontaneous abortion. One achieved a live birth without intervention.
Conclusion: Oral progestin is an effective temporizing fertility-sparing treatment for women with CAH/G1EC. Fertility specialist involvement is recommended due to the low live birth rate without intervention. Progestin therapy should be re-evaluated at 1 year in non-responders due to a low probability of success. Hysterectomy is recommended after childbearing due to a high recurrence rate.
Keywords: Conservative treatment; Endometrial atypical hyperplasia; Endometrial cancer; Fertility sparing; Progestin therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.Am J Obstet Gynecol. 2014 Mar;210(3):255.e1-4. doi: 10.1016/j.ajog.2013.11.001. Epub 2013 Nov 8. Am J Obstet Gynecol. 2014. PMID: 24211482
-
[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24284224 Chinese.
-
Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).Eur J Cancer. 2013 Mar;49(4):868-74. doi: 10.1016/j.ejca.2012.09.017. Epub 2012 Oct 13. Eur J Cancer. 2013. PMID: 23072814
-
Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Arch Gynecol Obstet. 2015. PMID: 25118836 Review.
-
Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.J Gynecol Oncol. 2023 Jul;34(4):e49. doi: 10.3802/jgo.2023.34.e49. Epub 2023 Mar 6. J Gynecol Oncol. 2023. PMID: 36929578 Free PMC article.
Cited by
-
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.Medicina (Kaunas). 2022 Sep 11;58(9):1256. doi: 10.3390/medicina58091256. Medicina (Kaunas). 2022. PMID: 36143933 Free PMC article. Review.
-
Breast cancer in the setting of fertility-sparing treatment for endometrial cancer.Gynecol Oncol Rep. 2014 Oct 27;10:30-1. doi: 10.1016/j.gore.2014.10.002. eCollection 2014 Dec. Gynecol Oncol Rep. 2014. PMID: 26075999 Free PMC article.
-
Effectiveness of Megestrol for the Treatment of Patients with Atypical Endometrial Hyperplasia or Endometrial Endometrioid Adenocarcinoma (Stage IA, Well Differentiated).J Res Pharm Pract. 2021 Dec 25;10(3):138-143. doi: 10.4103/jrpp.JRPP_20_128. eCollection 2021 Jul-Sep. J Res Pharm Pract. 2021. PMID: 35198507 Free PMC article.
-
Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.PLoS One. 2020 Apr 28;15(4):e0232231. doi: 10.1371/journal.pone.0232231. eCollection 2020. PLoS One. 2020. PMID: 32343732 Free PMC article.
-
Fertility preservation treatment of gynecological cancer patients in Spain: a national survey (GOFER study).Arch Gynecol Obstet. 2020 Mar;301(3):793-800. doi: 10.1007/s00404-020-05468-8. Epub 2020 Mar 2. Arch Gynecol Obstet. 2020. PMID: 32124016
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources